Trastuzumab Emtansine (T-DM1) is an antibody-drug conjugate — a newer class of cancer therapy that fuses a targeting antibody with a cytotoxic payload, so the chemotherapy component is delivered directly inside HER2-positive cancer cells rather than circulating throughout the whole body the way conventional chemotherapy does. This targeted-delivery mechanism is precisely why it's positioned as a step up from standard Trastuzumab in treatment guidelines, reserved for patients whose disease has progressed on or after first-line HER2 therapy.

• Approved indications: HER2-positive metastatic breast cancer following prior Trastuzumab and taxane-based chemotherapy; adjuvant therapy for residual invasive disease after neoadjuvant treatment and surgery
• Drug class: Antibody-drug conjugate (ADC) — Trastuzumab antibody + DM1 cytotoxic agent
• Administration: Single agent, given as IV infusion — not combined with additional chemotherapy, unlike standard Trastuzumab regimens
• Dosing cycle: Administered every 3 weeks under oncologist supervision
• Market positioning: Premium HER2-therapy tier — priced and marketed differently from standard Trastuzumab given its more complex manufacturing process and clinical role as later-line therapy

• Because T-DM1 carries both the cardiac risks associated with Trastuzumab and the additional toxicity of its cytotoxic payload, patients require a more intensive monitoring schedule than standard Trastuzumab therapy alone.

  • Hepatotoxicity: Liver function tests (ALT, AST, bilirubin) required before every infusion cycle — dose modification or discontinuation protocols apply based on severity grading
  • Cardiotoxicity: Same LVEF monitoring protocol as standard Trastuzumab — baseline echocardiogram/MUGA scan, repeated periodically through treatment
  • Peripheral neuropathy: Can occur and may require dose adjustment if it worsens
  • Thrombocytopenia: Regular platelet count monitoring required, more pronounced risk than with standard Trastuzumab
  • Pregnancy: Strictly contraindicated — effective contraception required during treatment and for 7 months after the final dose

Stock status: Available on request, both 100mg and 160mg strengths | Quote turnaround: Confirm strength, quantity, and destination country for a verified export quote

Given the conjugate's sensitivity to temperature excursions, we treat T-DM1 shipments with the same discipline as our most cold-chain-critical biologics — a break in the 2–8°C range at any point in transit can compromise the antibody-payload linkage before the product even reaches customs.

• Logistics: Strict 2–8°C cold-chain, GDP-compliant throughout
• Shipping method: Air freight prioritized over sea freight given the shorter acceptable excursion window
• Coverage: Global export markets, with documentation support tailored to destination-country requirements
• Tracking: Real-time shipment tracking with temperature-log verification available on request

What is Trastuzumab Emtansine used for?

Treats HER2-positive metastatic breast cancer after prior Trastuzumab and chemotherapy.

Get Trastuzumab Emtansine price from a GMP-compliant Indian supplier — how?

Send strength and destination country for a verified export quote.

How is it different from standard Trastuzumab?

It's an antibody-drug conjugate that delivers chemotherapy directly to HER2-positive cancer cells.

Does it require cardiac monitoring?

Yes, the same cardiac monitoring protocol as standard Trastuzumab applies.

Who supplies it from India?

WHO-GMP certified manufacturing partners with full export documentation.